Evidence map›Paper›PMID 41345269›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Impact of point-of-care multiplex PCR for Mycoplasma pneumoniae community-acquired pneumonia in the emergency department.

Jérémy Guenezan, Luc Deroche, Nicolas Marjanovic, Mélyne Piton, Bertrand Drugeon, Benjamin Bigaud, Martin Billaud, Nicolas Leveque, Olivier Mimoz

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jérémy GuenezanService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France. jeremyguenezan@gmail.com.
Luc DerocheLaboratoire de virologie et mycobactériologie, CHU de Poitiers, Poitiers, France.
Nicolas MarjanovicService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France.
Mélyne PitonService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France.
Bertrand DrugeonService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France.
Benjamin BigaudService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France.
Martin BillaudService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France.
Nicolas LevequeLaboratoire de virologie et mycobactériologie, CHU de Poitiers, Poitiers, France.
Olivier MimozService des Urgences SAMU SMUR, Faculté de Médecine, CHU Poitiers, France: Université de Poitiers, Poitiers, 86021, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCommunity-acquired pneumonia (CAP) due to Mycoplasma pneumoniae is a frequent and challenging diagnosis in Emergency Departments (EDs), often leading to unnecessarily broad-spectrum or ineffective antibiotic therapy. We hypothesize that rapid diagnostic tools, such as point-of-care (POC) devices, could improve initial antibiotic therapy appropriateness and reduce unnecessary additional diagnostic tests.

methodsWe conducted a retrospective, single-centre, study involving 81 patients visiting our ED with Mycoplasma pneumoniae CAP diagnosed between January 2023 and June 2024. Patients were divided into two groups depending on whether their nasopharyngeal swab, taken to detect viruses or selected bacteria such as Mycoplasma pneumoniae, was handled at the ED with a POC device (POC group) or at the main laboratory (Lab group). Primary outcome was the appropriateness of initial antibiotic therapy, defined as the use of macrolide (or tetracycline or fluoroquinolone in allergic patients) alone or, in case of severe disease, in combination with third-generation cephalosporin.

resultsInitial antibiotic therapy was more frequently appropriated in patients of the POC group than in patients of the Lab group (28 of 43 [65%] vs. 6 of 38 [16%], adjusted OR: 9.9, 95% confidence interval: 3.4 to 29.1; p < .001). Point-of-care testing was associated with fewer additional biological and radiological tests performed in the ED.

conclusionPOC improved the management of Mycoplasma pneumoniae CAP by increasing the appropriateness of initial antimicrobial therapy and reducing unnecessary additional diagnostic procedures. Larger multicentre studies are needed to confirm these findings, assess the impact on overall healthcare costs, and investigate the integration of POC devices into routine clinical workflows.

Indexed as

Community-Acquired InfectionsEmergency Service, HospitalMultiplex Polymerase Chain ReactionMycoplasma pneumoniaePneumonia, MycoplasmaPoint-of-Care SystemsPoint-of-Care TestingAdultAgedAnti-Bacterial AgentsCommunity-Acquired PneumoniaFemaleHumansMaleMiddle AgedRetrospective StudiesAnti-Bacterial AgentsAntimicrobial therapyCommunity-acquired pneumoniaEmergency medicineLaboratory testingMycoplasma pneumoniaePoint-of-care testing

Identifiers

PMID41345269

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.